Live Breaking News & Updates on Antonio Passaro

Stay updated with breaking news from Antonio passaro. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Amivantamab Offers Post-Progression Benefit in EGFRm NSCLC

Even if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed. ....

United States , University Of Virginia , Comunidad Autonoma De Cataluna , Maria Rosario Garcia Campelo , Ryand Gentzler , Enriqueta Felip , Merck Serono , Antonio Passaro , Daiichi Sankyo , Zofia Piotrowska , Eli Lilly , Society For Immunotherapy Of Cancer , Jazz Pharmaceuticals , University Hospitala Coru , European Institute Of Oncology , Janssen Pharmaceuticals , Bristol Myers Squibb , Investigational Drug Steering Committee , Boehringer Ingelheim , Hebron University Hospital , European Lung Cancer Congress , Hoosier Cancer Research Network , Cancer Center , Drug Administration , Big Ten Research Consortium , Scientific Review Committee ,

New Data From 2023 ESMO Congress Further Define the Evolving Role of ADCs in NSCLC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats. ....

Îe De France , Georgetown University , District Of Columbia , United States , Lombardi Cancer Center , France General , Institut Curie , Nicolas Girard , Stephenv Liu , Antonio Passaro , University Of Versailles Saint Quentin , Curie Montsouris Thorax Institute , European Society For Medical Oncology , Lombardi Comprehensive Cancer Center , European Institute Of Oncology , Medical Oncology , European Institute , May Inform , Considering Clinical Updates In Lung Cancer ,

Dr Passaro on the Significance of the TROPION-Lung05 Trial of Dato-DXd in NSCLC

Antonio Passaro, MD, PhD, medical oncologist, Division of Thoracic Oncology, European Institute of Oncology, discusses the significance of data from the phase 2 TROPION-Lung05 trial of datopotamab deruxtecan in patients with non–small cell lung cancer. ....

Antonio Passaro , Division Of Thoracic Oncology , European Institute Of Oncology , Thoracic Oncology , European Institute , Tropion Lung05 , Dato Dxd ,

Amivantamab Plus Chemo Deemed New Standard for NSCLC After Progression on Osimertinib

Adding amivantamab to chemotherapy can improve outcomes in patients with EGFR-mutant advanced NSCLC whose disease progressed on osimertinib. ....

Antonio Passaro , European Institute Of Oncology , European Institute ,

New Options Challenge Standard Treatments in EGFR-Mutant NSCLC

Amivantamab-based regimens improved oncologic outcomes, but with more side effects ....

United States , Soult Ukpyolsi , South Korea , Byoung Chul Cho , Passaroa Amivantamab , Antonio Passaro , Zosia Piotrowska , Yonsei Cancer Center , European Society For Medical Oncology , Hospital Cancer Center , European Institute Of Oncology , European Institute , European Society , Medical Oncology , Massachusetts General Hospital Cancer Center , Managing Editor , Medpage Today ,